AbbVie licenses OSE's chronic inflammation therapy for $48m upfront

Retrieved on: 2024-02-28 16:34:53

Tags for this article:

Immunology

Boehringer Ingelheim

AbbVie

Antibody-drug conjugate

ImmunoGen

Eli Lilly and Company

Click the tags to see associated articles and topics

AbbVie licenses OSE's chronic inflammation therapy for $48m upfront. View article details on HISWAI: https://www.pharmaceutical-technology.com/news/abbvie-licenses-oses-chronic-inflammation-therapy-for-48m-upfront/

Summary

The article discusses AbbVie's licensing of OSE Immunotherapeutics’ monoclonal antibody OSE-230 for chronic inflammation treatment, with ties to business intelligence in strategic pharmaceutical partnerships involving immunology-focused companies and innovative therapies like antibody-drug conjugates.

Article found on: www.pharmaceutical-technology.com

View Original Article